Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979121 · ClinicalTrials.gov registry record · Phase 3
Statins for Acutely Injured Lungs From Sepsis
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 745
- Enrollment target
NCT00979121 is a Phase 3 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 745 participants.
The verdict
NCT00979121, a Phase 3 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 745 participants
- Enrollment target
Study Summary
Objective: assess the efficacy and safety of oral rosuvastatin in patients with sepsis-induced Acute Lung Injury (ALI). Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.
Interventions
- DRUG Placebo
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 745 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00979121
The ClinicalTrials.gov registry entry for NCT00979121 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 745 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00979121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00979121 about?
NCT00979121 is a clinical study titled "Statins for Acutely Injured Lungs From Sepsis". Objective: assess the efficacy and safety of oral rosuvastatin in patients with sepsis-induced Acute Lung Injury (ALI). Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.
What is the current status of trial NCT00979121?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 745 participants. The study started on 2010-01. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00979121?
The interventions under investigation include: Placebo (DRUG), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT00979121?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.